
    
      The study is an extension of the primary vaccination study 711202/001 (MenC-TT-001). It
      comprises 5 groups: 4 parallel groups of toddlers vaccinated in study 711202/001 (group
      vaccinated with Meningitec™ is control group 1) and 1 group of naive subjects (no previous
      vaccination against MenC disease, control group 2). All subjects receive 1/5th dose Mencevax™
      ACWY and a concomitant dose of Infanrix hexa®. 2 blood samples: prior to and 1 month after
      vaccination.
    
  